One-year costs in patients with a history of or at risk for atherothrombosis in the United States

Elizabeth M. Mahoney, Kaijun Wang, David J. Cohen, Alan T. Hirsch, Mark J. Alberts, Kim Eagle, Frederique Mosse, Joseph D. Jackson, P. Gabriel Steg, Deepak L. Bhatt

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Background-Atherothrombosis is the underlying cause of cardiovascular, cerebrovascular, and peripheral arterial disease and is the leading cause of death in the industrialized world. The objectives of the present study are (1) to examine the annual costs associated with vascular events and interventions that require hospitalization, as well as long-term medication use for the management of associated risk factors, in a US population of outpatients with multiple atherothrombotic risk factors or a history of symptomatic disease and (2) to compare costs across patient subgroups defined according to specific arterial bed(s) affected and the number of affected arterial beds. Methods and Results-The international REduction of Atherothrombosis for Continued Health (REACH) Registry enrolled outpatients ≥45 years of age who had established coronary artery, cerebrovascular, or peripheral artery disease or ≥3 atherothrombotic risk factors. Data on risk factors, associated medications, and vascular hospitalizations and interventions were collected. Of the total 68 236-patient REACH cohort, 25 763 were enrolled from US sites. Complete 1-year data were available for 23 974 (93%) of the US patients. Annualized medication costs ranged from $2401 to $3481. Mean annual hospitalization costs per patient were $1344, $2864, $4824, and $8155 for patients with 0 (n=6145), 1 (n=14 353), 2 (n=3106), and 3 (n=370) affected arterial beds at baseline (P<0.0001 for trend). Among patients with 1 affected arterial bed, mean hospitalization costs were $2999, $2010, and $3911 for patients with coronary artery disease (n=11 063), cerebrovascular disease (n=2613), and peripheral arterial disease (n=677), respectively. Annualized medication costs ranged from $2401 to $3481. Conclusions-These results reveal the high economic burden of atherothrombosis-related clinical events and procedures and the especially high economic burden associated with polyvascular disease.

Original languageEnglish (US)
Pages (from-to)38-45
Number of pages8
JournalCirculation: Cardiovascular Quality and Outcomes
Volume1
Issue number1
DOIs
StatePublished - Sep 2008

Fingerprint

Costs and Cost Analysis
Peripheral Arterial Disease
Hospitalization
Blood Vessels
Outpatients
Economics
Cerebrovascular Disorders
Health
Registries
Coronary Artery Disease
Cause of Death
Coronary Vessels
Population

Keywords

  • Cerebrovascular disorders
  • Coronary disease
  • Costs
  • Peripheral vascular disease
  • Thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

One-year costs in patients with a history of or at risk for atherothrombosis in the United States. / Mahoney, Elizabeth M.; Wang, Kaijun; Cohen, David J.; Hirsch, Alan T.; Alberts, Mark J.; Eagle, Kim; Mosse, Frederique; Jackson, Joseph D.; Steg, P. Gabriel; Bhatt, Deepak L.

In: Circulation: Cardiovascular Quality and Outcomes, Vol. 1, No. 1, 09.2008, p. 38-45.

Research output: Contribution to journalArticle

Mahoney, EM, Wang, K, Cohen, DJ, Hirsch, AT, Alberts, MJ, Eagle, K, Mosse, F, Jackson, JD, Steg, PG & Bhatt, DL 2008, 'One-year costs in patients with a history of or at risk for atherothrombosis in the United States', Circulation: Cardiovascular Quality and Outcomes, vol. 1, no. 1, pp. 38-45. https://doi.org/10.1161/CIRCOUTCOMES.108.775247
Mahoney, Elizabeth M. ; Wang, Kaijun ; Cohen, David J. ; Hirsch, Alan T. ; Alberts, Mark J. ; Eagle, Kim ; Mosse, Frederique ; Jackson, Joseph D. ; Steg, P. Gabriel ; Bhatt, Deepak L. / One-year costs in patients with a history of or at risk for atherothrombosis in the United States. In: Circulation: Cardiovascular Quality and Outcomes. 2008 ; Vol. 1, No. 1. pp. 38-45.
@article{dd8d4e018b1348b987de65d288d7ad2d,
title = "One-year costs in patients with a history of or at risk for atherothrombosis in the United States",
abstract = "Background-Atherothrombosis is the underlying cause of cardiovascular, cerebrovascular, and peripheral arterial disease and is the leading cause of death in the industrialized world. The objectives of the present study are (1) to examine the annual costs associated with vascular events and interventions that require hospitalization, as well as long-term medication use for the management of associated risk factors, in a US population of outpatients with multiple atherothrombotic risk factors or a history of symptomatic disease and (2) to compare costs across patient subgroups defined according to specific arterial bed(s) affected and the number of affected arterial beds. Methods and Results-The international REduction of Atherothrombosis for Continued Health (REACH) Registry enrolled outpatients ≥45 years of age who had established coronary artery, cerebrovascular, or peripheral artery disease or ≥3 atherothrombotic risk factors. Data on risk factors, associated medications, and vascular hospitalizations and interventions were collected. Of the total 68 236-patient REACH cohort, 25 763 were enrolled from US sites. Complete 1-year data were available for 23 974 (93{\%}) of the US patients. Annualized medication costs ranged from $2401 to $3481. Mean annual hospitalization costs per patient were $1344, $2864, $4824, and $8155 for patients with 0 (n=6145), 1 (n=14 353), 2 (n=3106), and 3 (n=370) affected arterial beds at baseline (P<0.0001 for trend). Among patients with 1 affected arterial bed, mean hospitalization costs were $2999, $2010, and $3911 for patients with coronary artery disease (n=11 063), cerebrovascular disease (n=2613), and peripheral arterial disease (n=677), respectively. Annualized medication costs ranged from $2401 to $3481. Conclusions-These results reveal the high economic burden of atherothrombosis-related clinical events and procedures and the especially high economic burden associated with polyvascular disease.",
keywords = "Cerebrovascular disorders, Coronary disease, Costs, Peripheral vascular disease, Thrombosis",
author = "Mahoney, {Elizabeth M.} and Kaijun Wang and Cohen, {David J.} and Hirsch, {Alan T.} and Alberts, {Mark J.} and Kim Eagle and Frederique Mosse and Jackson, {Joseph D.} and Steg, {P. Gabriel} and Bhatt, {Deepak L.}",
year = "2008",
month = "9",
doi = "10.1161/CIRCOUTCOMES.108.775247",
language = "English (US)",
volume = "1",
pages = "38--45",
journal = "Circulation: Cardiovascular Quality and Outcomes",
issn = "1941-7713",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - One-year costs in patients with a history of or at risk for atherothrombosis in the United States

AU - Mahoney, Elizabeth M.

AU - Wang, Kaijun

AU - Cohen, David J.

AU - Hirsch, Alan T.

AU - Alberts, Mark J.

AU - Eagle, Kim

AU - Mosse, Frederique

AU - Jackson, Joseph D.

AU - Steg, P. Gabriel

AU - Bhatt, Deepak L.

PY - 2008/9

Y1 - 2008/9

N2 - Background-Atherothrombosis is the underlying cause of cardiovascular, cerebrovascular, and peripheral arterial disease and is the leading cause of death in the industrialized world. The objectives of the present study are (1) to examine the annual costs associated with vascular events and interventions that require hospitalization, as well as long-term medication use for the management of associated risk factors, in a US population of outpatients with multiple atherothrombotic risk factors or a history of symptomatic disease and (2) to compare costs across patient subgroups defined according to specific arterial bed(s) affected and the number of affected arterial beds. Methods and Results-The international REduction of Atherothrombosis for Continued Health (REACH) Registry enrolled outpatients ≥45 years of age who had established coronary artery, cerebrovascular, or peripheral artery disease or ≥3 atherothrombotic risk factors. Data on risk factors, associated medications, and vascular hospitalizations and interventions were collected. Of the total 68 236-patient REACH cohort, 25 763 were enrolled from US sites. Complete 1-year data were available for 23 974 (93%) of the US patients. Annualized medication costs ranged from $2401 to $3481. Mean annual hospitalization costs per patient were $1344, $2864, $4824, and $8155 for patients with 0 (n=6145), 1 (n=14 353), 2 (n=3106), and 3 (n=370) affected arterial beds at baseline (P<0.0001 for trend). Among patients with 1 affected arterial bed, mean hospitalization costs were $2999, $2010, and $3911 for patients with coronary artery disease (n=11 063), cerebrovascular disease (n=2613), and peripheral arterial disease (n=677), respectively. Annualized medication costs ranged from $2401 to $3481. Conclusions-These results reveal the high economic burden of atherothrombosis-related clinical events and procedures and the especially high economic burden associated with polyvascular disease.

AB - Background-Atherothrombosis is the underlying cause of cardiovascular, cerebrovascular, and peripheral arterial disease and is the leading cause of death in the industrialized world. The objectives of the present study are (1) to examine the annual costs associated with vascular events and interventions that require hospitalization, as well as long-term medication use for the management of associated risk factors, in a US population of outpatients with multiple atherothrombotic risk factors or a history of symptomatic disease and (2) to compare costs across patient subgroups defined according to specific arterial bed(s) affected and the number of affected arterial beds. Methods and Results-The international REduction of Atherothrombosis for Continued Health (REACH) Registry enrolled outpatients ≥45 years of age who had established coronary artery, cerebrovascular, or peripheral artery disease or ≥3 atherothrombotic risk factors. Data on risk factors, associated medications, and vascular hospitalizations and interventions were collected. Of the total 68 236-patient REACH cohort, 25 763 were enrolled from US sites. Complete 1-year data were available for 23 974 (93%) of the US patients. Annualized medication costs ranged from $2401 to $3481. Mean annual hospitalization costs per patient were $1344, $2864, $4824, and $8155 for patients with 0 (n=6145), 1 (n=14 353), 2 (n=3106), and 3 (n=370) affected arterial beds at baseline (P<0.0001 for trend). Among patients with 1 affected arterial bed, mean hospitalization costs were $2999, $2010, and $3911 for patients with coronary artery disease (n=11 063), cerebrovascular disease (n=2613), and peripheral arterial disease (n=677), respectively. Annualized medication costs ranged from $2401 to $3481. Conclusions-These results reveal the high economic burden of atherothrombosis-related clinical events and procedures and the especially high economic burden associated with polyvascular disease.

KW - Cerebrovascular disorders

KW - Coronary disease

KW - Costs

KW - Peripheral vascular disease

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=68349161985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68349161985&partnerID=8YFLogxK

U2 - 10.1161/CIRCOUTCOMES.108.775247

DO - 10.1161/CIRCOUTCOMES.108.775247

M3 - Article

C2 - 20031786

AN - SCOPUS:68349161985

VL - 1

SP - 38

EP - 45

JO - Circulation: Cardiovascular Quality and Outcomes

JF - Circulation: Cardiovascular Quality and Outcomes

SN - 1941-7713

IS - 1

ER -